REFERENCES
1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367:eaau6977.
2. Platko K, Haas-Neill S, Aziz T, Al-Nedawi K. The role of circulating extracellular vesicles in breast cancer classification and molecular subtyping. Breast J 2019;25:691-5.
3. Vietri M, Radulovic M, Stenmark H. The many functions of ESCRTs. Nat Rev Mol Cell Biol 2020;21:25-42.
4. Song L, Tang S, Han X, et al. KIBRA controls exosome secretion via inhibiting the proteasomal degradation of Rab27a. Nat Commun 2019;10:1639.
6. Wu H, Fu M, Liu J, et al. The role and application of small extracellular vesicles in gastric cancer. Mol Cancer 2021;20:71.
7. Li K, Chen Y, Li A, Tan C, Liu X. Exosomes play roles in sequential processes of tumor metastasis. Int J Cancer 2019;144:1486-95.
8. Hernández-Barranco A, Nogués L, Peinado H. Could extracellular vesicles contribute to generation or awakening of “sleepy” metastatic niches? Front Cell Dev Biol 2021;9:625221.
9. Li I, Nabet BY. Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. Mol Cancer 2019;18:32.
10. Dai Y, Liu Y, Li J, Jin M, Yang H, Huang G. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway. Bioengineered 2022;13:13906-18.
11. Faict S, Oudaert I, D'Auria L, et al. The transfer of sphingomyelinase contributes to drug resistance in multiple myeloma. Cancers 2019;11:1823.
14. Zaal EA, Berkers CR. The influence of metabolism on drug response in cancer. Front Oncol 2018;8:500.
15. Sun H, Hu C, Zheng X, Zhuang J, Wei X, Cai J. Correlation between serum lipid levels and endocrine resistance in patients with ER-positive breast cancer. Medicine 2023;102:e35048.
16. Yang SM, Kim J, Lee JY, Lee JS, Lee JM. Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma. BMB Rep 2023;56:600-5.
17. Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat 2021;59:100796.
18. Assaraf YG, Brozovic A, Gonçalves AC, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat 2019;46:100645.
19. Theile D, Wizgall P. Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection? Naunyn Schmiedebergs Arch Pharmacol 2021;394:1621-32.
20. Wang JQ, Yang Y, Cai CY, et al. Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance. Drug Resist Updat 2021;54:100743.
21. Ozyerli-Goknar E, Bagci-Onder T. Epigenetic deregulation of apoptosis in cancers. Cancers 2021;13:3210.
22. Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. DNA repair pathways in cancer therapy and resistance. Front Pharmacol 2020;11:629266.
23. Desbats MA, Giacomini I, Prayer-Galetti T, Montopoli M. Metabolic plasticity in chemotherapy resistance. Front Oncol 2020;10:281.
24. Lin J, Xia L, Liang J, et al. The roles of glucose metabolic reprogramming in chemo- and radio-resistance. J Exp Clin Cancer Res 2019;38:218.
25. Hamadneh L, Abuarqoub R, Alhusban A, Bahader M. Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells. Sci Rep 2020;10:21933.
26. Sun H, Wang H, Wang X, et al. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics 2020;10:6928-45.
27. Chen T, Xu ZG, Luo J, et al. NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance. Cell Metab 2023;35:1782-98.e8.
28. Fang Y, Zhan Y, Xie Y, et al. Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology 2022;75:1386-401.
29. Park GB, Jeong JY, Choi S, Yoon YS, Kim D. Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells. Anticancer Drugs 2022;33:e370-80.
30. Hoshi S, Meguro S, Imai H, et al. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Sci 2021;112:1899-910.
31. Liu H, Lyu H, Jiang G, et al. ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer. Cancer Res 2022;82:3974-86.
32. Das CK, Parekh A, Parida PK, Bhutia SK, Mandal M. Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer. Biochim Biophys Acta Mol Cell Res 2019;1866:1004-18.
33. Wang S, Zhou L, Ji N, et al. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resist Updat 2023;69:100976.
34. Jiang X, Guo S, Wang S, et al. EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling. Cancer Res 2022;82:831-45.
35. Chen X, Luo R, Zhang Y, et al. Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer. Nat Commun 2022;13:7160.
36. Zheng Y, Zhan Y, Zhang Y, et al. Hexokinase 2 confers radio-resistance in hepatocellular carcinoma by promoting autophagy-dependent degradation of AIMP2. Cell Death Dis 2023;14:488.
37. Lee HJ, Li CF, Ruan D, et al. Non-proteolytic ubiquitination of Hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion. Nat Commun 2019;10:2625.
38. Ishfaq M, Bashir N, Riaz SK, et al. Expression of HK2, PKM2, and PFKM is associated with metastasis and late disease onset in breast cancer patients. Genes 2022;13:549.
39. Lypova N, Telang S, Chesney J, Imbert-Fernandez Y. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival. J Biol Chem 2019;294:10530-43.
40. Jones BC, Pohlmann PR, Clarke R, Sengupta S. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer Metastasis Rev 2022;41:447-58.
41. Chang YC, Yang YF, Chiou J, et al. Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness. Cell Death Dis 2020;11:195.
42. Li Q, Qin T, Bi Z, et al. Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat Commun 2020;11:1456.
43. Qin Y, Ma X, Guo C, Cai S, Ma H, Zhao L. MeCP2 confers 5-fluorouracil resistance in gastric cancer via upregulating the NOX4/PKM2 pathway. Cancer Cell Int 2022;22:86.
44. Zhou JW, Tang JJ, Sun W, Wang H. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma. Mol Med 2019;25:11.
45. İlhan M. Non-metabolic functions of pyruvate kinase M2: PKM2 in tumorigenesis and therapy resistance. Neoplasma 2022;69:747-54.
46. Wang X, Zhang H, Yang H, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol 2020;14:539-55.
47. Wong TL, Ng KY, Tan KV, et al. CRAF methylation by PRMT6 regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. Hepatology 2020;71:1279-96.
48. Cai Y, Gao Q, Meng JH, Chen L. Puerarin suppresses glycolysis and increases cisplatin chemosensitivity in oral squamous cell carcinoma via FBXW7/mTOR signaling. Nutr Cancer 2023;75:1028-37.
49. Zhang Y, Song Y, Ren S, et al. GPER-mediated stabilization of HIF-1α contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells. Oncogene 2023;42:184-97.
50. Ma L, Liu W, Xu A, et al. Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect. Cancer Sci 2020;111:2028-40.
51. Ma L, Zong X. Metabolic symbiosis in chemoresistance: refocusing the role of aerobic glycolysis. Front Oncol 2020;10:5.
52. Zong S, Dai W, Fang W, Guo X, Wang K. SIK2 promotes cisplatin resistance induced by aerobic glycolysis in breast cancer cells through PI3K/AKT/mTOR signaling pathway. Biosci Rep 2020:BSR20201302.
53. Yu X, Gao X, Mao X, et al. Knockdown of FOXO6 inhibits glycolysis and reduces cell resistance to paclitaxel in HCC cells via PI3K/Akt signaling pathway. Onco Targets Ther 2020;13:1545-56.
54. Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res 2020;39:24.
55. He Y, Wang X, Lu W, et al. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis 2022;13:118.
56. Xu F, Huang M, Chen Q, et al. LncRNA HIF1A-AS1 promotes gemcitabine resistance of pancreatic cancer by enhancing glycolysis through modulating the AKT/YB1/HIF1α pathway. Cancer Res 2021;81:5678-91.
57. Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J Exp Clin Cancer Res 2021;40:390.
58. Blagden SP, Hamilton AL, Mileshkin L, et al. Phase IB dose escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer. Clin Cancer Res 2019;25:1472-8.
59. Nam SO, Yotsumoto F, Miyata K, et al. Warburg effect regulated by amphiregulin in the development of colorectal cancer. Cancer Med 2015;4:575-87.
60. Wang G, Wang JJ, Yin PH, et al. New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy. J Cell Physiol 2018;234:348-68.
61. Choi MC, Kim SK, Choi YJ, et al. Role of monocarboxylate transporter I/lactate dehydrogenase B-mediated lactate recycling in tamoxifen-resistant breast cancer cells. Arch Pharm Res 2023;46:907-23.
62. Feng Y, Zhang X, Zhang S, et al. PGAM1 promotes glycolytic metabolism and paclitaxel resistance via pyruvic acid production in ovarian cancer cells. Front Biosci 2022;27:262.
63. Tan Y, Li J, Zhao G, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun 2022;13:4554.
64. Talebi A, de Laat V, Spotbeen X, et al. Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy. J Exp Clin Cancer Res 2023;42:92.
65. Menendez JA, Papadimitropoulou A, Vander Steen T, et al. Fatty acid synthase confers tamoxifen resistance to ER+/HER2+ breast cancer. Cancers 2021;13:1132.
66. Gruslova A, McClellan B, Balinda HU, et al. FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res Treat 2021;187:375-86.
67. Yu L, Wang X, Du Y, Zhang X, Ling Y. FASN knockdown inhibited anoikis resistance of gastric cancer cells via P-ERK1/2/Bcl-xL pathway. Gastroenterol Res Pract 2021;2021:6674204.
68. Yang T, Qiao S, Zhu X. High-dose radiation-resistant lung cancer cells stored many functional lipid drops through JAK2/p-STAT3/FASN pathway. J Cancer Res Clin Oncol 2023;149:14169-83.
69. Souchek JJ, Laliwala A, Houser L, Muraskin L, Vu Q, Mohs AM. Fatty acid synthase inhibitors enhance microtubule-stabilizing and microtubule-destabilizing drugs in taxane-resistant prostate cancer cells. ACS Pharmacol Transl Sci 2023;6:1859-69.
70. Stamatakos S, Beretta GL, Vergani E, et al. Deregulated FASN expression in BRAF inhibitor-resistant melanoma cells unveils new targets for drug combinations. Cancers 2021;13:2284.
71. Polonio-Alcalá E, Porta R, Ruiz-Martínez S, et al. AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models. Biomed Pharmacother 2022;156:113942.
72. Talebi A, Dehairs J, Rambow F, et al. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nat Commun 2018;9:2500.
73. Bacci M, Lorito N, Smiriglia A, et al. Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER+ breast cancer. Sci Transl Med 2024;16:eadf9874.
74. Wang X, He S, Gu Y, et al. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis. EBioMedicine 2019;40:251-62.
76. Fu H, He Y, Qi L, et al. cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells. Cancer Lett 2017;403:260-70.
77. Cen B, Lang JD, Du Y, et al. Prostaglandin E2 induces miR675-5p to promote colorectal tumor metastasis via modulation of p53 expression. Gastroenterology 2020;158:971-84.e10.
78. Chen L, Fu H, Luo Y, et al. cPLA2α mediates TGF-β-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signaling. Cell Death Dis 2017;8:e2728.
79. Wang T, Jing B, Xu D, et al. PTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model. Oncogene 2020;39:3179-94.
80. Wculek SK, Malanchi I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 2015;528:413-7.
81. Nosaka T, Baba T, Tanabe Y, et al. Alveolar macrophages drive hepatocellular carcinoma lung metastasis by generating leukotriene B4. J Immunol 2018;200:1839-52.
82. Li P, Lu M, Shi J, et al. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nat Immunol 2020;21:1444-55.
83. Krzeszinski JY, Schwaid AG, Cheng WY, et al. Lipid osteoclastokines regulate breast cancer bone metastasis. Endocrinology 2017;158:477-89.
84. Chen Q, Pan Z, Zhao M, et al. High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer. J Cell Physiol 2018;233:6722-32.
85. Zhang J, Li Q, Wu Y, et al. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell Commun Signal 2019;17:15.
86. Wu H, Liu B, Chen Z, Li G, Zhang Z. MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1α/CEBPB axis to promote stemness and chemo-resistance of gastric cancer. Cell Death Dis 2020;11:233.
87. Jayawardhana AMDS, Stilgenbauer M, Datta P, et al. Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36. Chem Commun 2020;56:10706-9.
88. Mukherjee A, Chiang CY, Daifotis HA, et al. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res 2020;80:1748-61.
89. Hillowe A, Gordon C, Wang L, et al. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells. PLoS One 2023;18:e0292483.
90. Watt MJ, Clark AK, Selth LA, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med 2019;11:eaau5758.
91. Alicea GM, Rebecca VW, Goldman AR, et al. Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter FATP2. Cancer Discov 2020;10:1282-95.
92. Du Q, Tan Z, Shi F, et al. PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation. Cancer Sci 2019;110:2050-62.
93. Wan H, Xu B, Zhu N, Ren B. PGC-1α activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer. Tumori 2020;106:55-63.
94. Liu Z, Liu W, Wang W, et al. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proc Natl Acad Sci U S A 2023;120:e2302878120.
95. Jiang C, Zhu Y, Chen H, et al. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. Cell Death Dis 2023;14:653.
96. Heiserman JP, Minhas Z, Nikpayam E, Cheon DJ. Targeting heat shock protein 27 and fatty acid oxidation augments cisplatin treatment in cisplatin-resistant ovarian cancer cell lines. Int J Mol Sci 2023;24:12638.
97. Han S, Wei R, Zhang X, et al. CPT1A/2-mediated FAO enhancement - A metabolic target in radioresistant breast cancer. Front Oncol 2019;9:1201.
98. Shen S, Faouzi S, Souquere S, et al. Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep 2020;33:108421.
99. Geneste A, Duong MN, Molina L, et al. Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib. BMC Pharmacol Toxicol 2020;21:61.
100. Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol 2019;20:137-55.
101. Grabner GF, Xie H, Schweiger M, Zechner R. Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nat Metab 2021;3:1445-65.
102. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010;140:49-61.
103. Rozeveld CN, Johnson KM, Zhang L, Razidlo GL. KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL. Cancer Res 2020;80:4932-45.
104. Wright HJ, Hou J, Xu B, et al. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci U S A 2017;114:E6556-65.
105. Criscuolo D, Avolio R, Calice G, et al. Cholesterol homeostasis modulates platinum sensitivity in human ovarian cancer. Cells 2020;9:828.
106. VandeKopple MJ, Wu J, Auer EN, Giaccia AJ, Denko NC, Papandreou I. HILPDA regulates lipid metabolism, lipid droplet abundance, and response to microenvironmental stress in solid tumors. Mol Cancer Res 2019;17:2089-101.
107. Tse C, Warner A, Farook R, Cronin JG. Phytochemical targeting of STAT3 orchestrated lipid metabolism in therapy-resistant cancers. Biomolecules 2020;10:1118.
108. Cruz ALS, Barreto EA, Fazolini NPB, Viola JPB, Bozza PT. Lipid droplets: platforms with multiple functions in cancer hallmarks. Cell Death Dis 2020;11:105.
109. Yang WH, Huang Z, Wu J, Ding CC, Murphy SK, Chi JT. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer. Mol Cancer Res 2020;18:79-90.
110. Alexa-Stratulat T, Pešić M, Gašparović AČ, Trougakos IP, Riganti C. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg. Drug Resist Updat 2019;46:100643.
111. Dubey R, Stivala CE, Nguyen HQ, et al. Lipid droplets can promote drug accumulation and activation. Nat Chem Biol 2020;16:206-13.
112. Englinger B, Laemmerer A, Moser P, et al. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. Int J Cancer 2020;147:1680-93.
113. Sirois I, Aguilar-Mahecha A, Lafleur J, et al. A unique morphological phenotype in chemoresistant triple-negative breast cancer reveals metabolic reprogramming and PLIN4 expression as a molecular vulnerability. Mol Cancer Res 2019;17:2492-507.
114. Curtarello M, Tognon M, Venturoli C, et al. Rewiring of lipid metabolism and storage in ovarian cancer cells after anti-VEGF therapy. Cells 2019;8:1601.
115. She K, Fang S, Du W, et al. SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals. Cancer Cell Int 2019;19:103.
116. Huang Q, Wang Q, Li D, et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res 2019;38:129.
117. Tan SK, Mahmud I, Fontanesi F, et al. Obesity-dependent adipokine chemerin suppresses fatty acid oxidation to confer ferroptosis resistance. Cancer Discov 2021;11:2072-93.
118. Song X, Liu J, Kuang F, et al. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. Cell Rep 2021;34:108767.
119. Lee H, Horbath A, Kondiparthi L, et al. Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nat Commun 2024;15:79.
120. Luis G, Godfroid A, Nishiumi S, et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol 2021;43:102006.
121. Wang SA, Wu YC, Yang FM, Hsu FL, Zhang K, Hung JJ. NCI677397 targeting USP24-mediated induction of lipid peroxidation induces ferroptosis in drug-resistant cancer cells. Mol Oncol 2024;18:2255-76.
122. Luo J, Li Y, Li Y, et al. Reversing ferroptosis resistance in breast cancer via tailored lipid and iron presentation. ACS Nano 2023;17:25257-68.
123. Thomas M, Davis T, Nell T, Sishi B, Engelbrecht AM. Amino acid starvation sensitizes resistant breast cancer to doxorubicin-induced cell death. Front Cell Dev Biol 2020;8:565915.
124. Dash S, Ueda T, Komuro A, et al. MYC/glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance. Mol Cancer Res 2023;21:444-57.
125. Xu L, Zhao B, Butler W, et al. Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. Oncogene 2022;41:1140-54.
126. Zhou X, Zhou R, Rao X, et al. Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer. Cell Death Dis 2022;13:636.
127. Kim G, Jang SK, Kim YJ, et al. Inhibition of glutamine uptake resensitizes paclitaxel resistance in SKOV3-TR ovarian cancer cell via mTORC1/S6K signaling pathway. Int J Mol Sci 2022;23:8761.
128. Wang Z, Li T, Li R, et al. Sijunzi Tang improves gefitinib resistance by regulating glutamine metabolism. Biomed Pharmacother 2023;167:115438.
129. Chen P, Liu XQ, Lin X, Gao LY, Zhang S, Huang X. Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol Ther Oncolytics 2021;20:228-39.
130. Lee ACK, Lau PM, Kwan YW, Kong SK. Mitochondrial fuel dependence on glutamine drives chemo-resistance in the cancer stem cells of hepatocellular carcinoma. Int J Mol Sci 2021;22:3315.
131. Ren J, Zhao C, Sun R, et al. Augmented drug resistance of osteosarcoma cells within decalcified bone matrix scaffold: The role of glutamine metabolism. Int J Cancer 2024;154:1626-38.
132. Morotti M, Zois CE, El-Ansari R, et al. Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. Br J Cancer 2021;124:494-505.
133. Ying L, Cheng M, Lu Y, et al. Glutamine metabolism scoring predicts prognosis and therapeutic resistance in hepatocellular carcinoma. Pathol Oncol Res 2021;27:1610075.
134. Fu S, Li Z, Xiao L, et al. Glutamine synthetase promotes radiation resistance via facilitating nucleotide metabolism and subsequent DNA damage repair. Cell Rep 2019;28:1136-43.e4.
135. Pan M, Zorbas C, Sugaya M, et al. Glutamine deficiency in solid tumor cells confers resistance to ribosomal RNA synthesis inhibitors. Nat Commun 2022;13:3706.
136. Okazaki S, Umene K, Yamasaki J, et al. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma. Cancer Sci 2019;110:3453-63.
137. Yoo HC, Park SJ, Nam M, et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab 2020;31:267-83.e12.
138. Li B, Cao Y, Meng G, et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine 2019;39:239-54.
139. Hu Q, Dai J, Zhang Z, et al. ASS1-mediated reductive carboxylation of cytosolic glutamine confers ferroptosis resistance in cancer cells. Cancer Res 2023;83:1646-65.
140. Kim JH, Lee J, Im SS, et al. Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer. Exp Mol Med 2024;56:1013-26.
141. Ishak Gabra MB, Yang Y, Li H, et al. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nat Commun 2020;11:3326.
142. Abid MA, Abid MB. Commentary: dietary methionine influences therapy in mouse cancer models and alters human metabolism. Front Oncol 2020;10:1071.
143. Gao X, Sanderson SM, Dai Z, et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 2019;572:397-401.
144. Wang Z, Yip LY, Lee JHJ, et al. Methionine is a metabolic dependency of tumor-initiating cells. Nat Med 2019;25:825-37.
145. Strekalova E, Malin D, Weisenhorn EMM, et al. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells. Breast Cancer Res Treat 2019;175:39-50.
146. Bacci M, Lorito N, Ippolito L, et al. Reprogramming of amino acid transporters to support aspartate and glutamate dependency sustains endocrine resistance in breast cancer. Cell Rep 2019;28:104-18.e8.
147. Sun J, Nagel R, Zaal EA, et al. SLC1A3 contributes to L-asparaginase resistance in solid tumors. EMBO J 2019;38:e102147.
148. Krall AS, Mullen PJ, Surjono F, et al. Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. Cell Metab 2021;33:1013-26.e6.
149. Jiang J, Srivastava S, Seim G, et al. Promoter demethylation of the asparagine synthetase gene is required for ATF4-dependent adaptation to asparagine depletion. J Biol Chem 2019;294:18674-84.
150. Hinze L, Pfirrmann M, Karim S, et al. Synthetic lethality of wnt pathway activation and asparaginase in drug-resistant acute leukemias. Cancer Cell 2019;35:664-76.e7.
151. Saito Y, Li L, Coyaud E, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer. Nature 2019;569:275-9.
152. Shindo H, Harada-Shoji N, Ebata A, et al. Targeting amino acid metabolic reprogramming via L-type amino acid transporter 1 (LAT1) for endocrine-resistant breast cancer. Cancers 2021;13:4375.
153. Wang Y, Zhang J, Ren S, et al. Branched-chain amino acid metabolic reprogramming orchestrates drug resistance to EGFR tyrosine kinase inhibitors. Cell Rep 2019;28:512-25.e6.
154. Sivanand S, Vander Heiden MG. Emerging roles for branched-chain amino acid metabolism in cancer. Cancer Cell 2020;37:147-56.
155. Luo L, Sun W, Zhu W, et al. BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism. Cell Death Dis 2021;12:169.
156. Montrose DC, Saha S, Foronda M, et al. Exogenous and endogenous sources of serine contribute to colon cancer metabolism, growth, and resistance to 5-fluorouracil. Cancer Res 2021;81:2275-88.
157. Engel AL, Lorenz NI, Klann K, et al. Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br J Cancer 2020;122:1391-8.
158. Zhao X, Fu J, Tang W, Yu L, Xu W. Inhibition of serine metabolism promotes resistance to cisplatin in gastric cancer. Onco Targets Ther 2020;13:4833-42.
159. Hu W, Xu Z, Zhu S, et al. Small extracellular vesicle-mediated Hsp70 intercellular delivery enhances breast cancer adriamycin resistance. Free Radic Biol Med 2021;164:85-95.
160. Wu J, Yuan M, Shen J, et al. Effect of modified Jianpi Yangzheng on regulating content of PKM2 in gastric cancer cells-derived exosomes. Phytomedicine 2022;103:154229.
161. Zhou S, Lan Y, Li Y, Li Z, Pu J, Wei L. Hypoxic tumor-derived exosomes induce M2 macrophage polarization via PKM2/AMPK to promote lung cancer progression. Cell Transplant 2022;31:9636897221106998.
162. Li G, Xiong Z, Li Y, et al. Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2. Discov Oncol 2024;15:110.
163. Wang D, Zhao C, Xu F, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics 2021;11:2860-75.
164. Alharbi M, Lai A, Sharma S, et al. Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence. Cancers 2021;13:3388.
165. Wang C, Xu J, Yuan D, et al. Exosomes carrying ALDOA and ALDH3A1 from irradiated lung cancer cells enhance migration and invasion of recipients by accelerating glycolysis. Mol Cell Biochem 2020;469:77-87.
166. Wu X, Zhou Z, Xu S, et al. Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. Cancer Lett 2020;478:93-106.
167. Sung JS, Kang CW, Kang S, et al. ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts. Oncogene 2020;39:664-76.
168. Morrissey SM, Zhang F, Ding C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab 2021;33:2040-58.e10.
169. Wang S, Su X, Xu M, et al. Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem Cell Res Ther 2019;10:117.
170. Lazar I, Clement E, Dauvillier S, et al. Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer. Cancer Res 2016;76:4051-7.
171. Clement E, Lazar I, Attané C, et al. Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J 2020;39:e102525.
172. Zhang Q, Deng T, Zhang H, et al. Adipocyte-derived exosomal MTTP suppresses ferroptosis and promotes chemoresistance in colorectal cancer. Adv Sci 2022;9:e2203357.
173. Yang Y, Gu H, Zhang K, et al. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. BMC Cancer 2023;23:789.
174. Lee HC, Ou CH, Huang YC, et al. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene 2021;40:2407-21.
175. Yang SJ, Wang DD, Li J, et al. Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer. Gene 2017;623:5-14.
176. Hu X, Ma Z, Xu B, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun 2023;43:909-37.
177. Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech 2021;14:dmm047662.
178. Qi R, Bai Y, Li K, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat 2023;68:100960.
179. Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer 2020;19:43.
180. Chang Y, Gao X, Jiang Y, et al. Alpha-hederin reprograms multi-miRNAs activity and overcome small extracellular vesicles-mediated paclitaxel resistance in NSCLC. Front Pharmacol 2024;15:1257941.
181. Alharbi M, Sharma S, Guanzon D, et al. miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer. Nanomedicine 2020;28:102207.
182. Zhuang L, Zhang B, Liu X, et al. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Cell Biol Int 2021;45:2140-9.
183. Wang H, Wang L, Pan H, et al. Exosomes derived from macrophages enhance aerobic glycolysis and chemoresistance in lung cancer by stabilizing c-myc via the inhibition of NEDD4L. Front Cell Dev Biol 2020;8:620603.
184. Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol 2019;21:498-510.
185. Li Y, Zhao Z, Liu W, Li X. SNHG3 functions as miRNA sponge to promote breast cancer cells growth through the metabolic reprogramming. Appl Biochem Biotechnol 2020;191:1084-99.
186. Zhang H, Wang M, He Y, et al. Chemotoxicity-induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells. Cell Death Dis 2021;12:1116.
187. Li C, Li X. Exosome-derived circ_0094343 promotes chemosensitivity of colorectal cancer cells by regulating glycolysis via the miR-766-5p/TRIM67 axis. Contrast Media Mol Imaging 2022;2022:2878557.
188. Shi Q, Ji T, Ma Z, Tan Q, Liang J. Serum exosomes-based biomarker circ_0008928 regulates cisplatin sensitivity, tumor progression, and glycolysis metabolism by miR-488/HK2 axis in cisplatin-resistant nonsmall cell lung carcinoma. Cancer Biother Radiopharm 2023;38:558-71.
189. Ma J, Qi G, Li L. A novel serum exosomes-based biomarker hsa_circ_0002130 facilitates osimertinib-resistance in non-small cell lung cancer by sponging miR-498. Onco Targets Ther 2020;13:5293-307.
190. Zeng Z, Zhao Y, Chen Q, et al. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Oncogene 2021;40:5505-17.
191. Tan WQ, Yuan L, Wu XY, He CG, Zhu SC, Ye M. Exosome-delivered circular RNA DLGAP4 induces chemoresistance via miR-143-HK2 axis in neuroblastoma. Cancer Biomark 2022;34:375-84.
192. Wang B, Wang X, Hou D, et al. Exosomes derived from acute myeloid leukemia cells promote chemoresistance by enhancing glycolysis-mediated vascular remodeling. J Cell Physiol 2019;234:10602-14.
193. Li F, Zhan L, Dong Q, et al. Tumor-derived exosome-educated hepatic stellate cells regulate lactate metabolism of hypoxic colorectal tumor cells via the IL-6/STAT3 pathway to confer drug resistance. Onco Targets Ther 2020;13:7851-64.
194. Chen Y, Wu J, Zhai L, et al. Metabolic regulation of homologous recombination repair by MRE11 lactylation. Cell 2024;187:294-311.e21.
195. Fang K, Chen X, Qiu F, Xu J, Xiong H, Zhang Z. Serum-derived exosomes-mediated circular RNA ARHGAP10 modulates the progression of non-small cell lung cancer through the miR-638/FAM83F axis. Cancer Biother Radiopharm 2022;37:96-110.
196. Tang KD, Wan Y, Zhang X, et al. Proteomic alterations in salivary exosomes derived from human papillomavirus-driven oropharyngeal cancer. Mol Diagn Ther 2021;25:505-15.
197. Lin J, Wang X, Zhai S, et al. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. J Hematol Oncol 2022;15:128.
198. Yi X, Li Y, Hu X, Wang F, Liu T. Changes in phospholipid metabolism in exosomes of hormone-sensitive and hormone-resistant prostate cancer cells. J Cancer 2021;12:2893-902.
199. Sanchez JI, Jiao J, Kwan SY, et al. Lipidomic profiles of plasma exosomes identify candidate biomarkers for early detection of hepatocellular carcinoma in patients with cirrhosis. Cancer Prev Res 2021;14:955-62.
200. Tao L, Zhou J, Yuan C, et al. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabolomics 2019;15:86.
201. Palacios-Ferrer JL, García-Ortega MB, Gallardo-Gómez M, et al. Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma. Mol Oncol 2021;15:407-28.
202. Ou B, Liu Y, Gao Z, et al. Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m6A demethylation. Cell Death Dis 2022;13:905.
203. Pan Y, Lu X, Shu G, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma. Cancer Res 2023;83:103-16.
204. Wan L, Xia T, Du Y, et al. Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells. FASEB J 2019;33:8530-42.
205. Lv B, Zhu W, Feng C. Coptisine blocks secretion of exosomal circCCT3 from cancer-associated fibroblasts to reprogram glucose metabolism in hepatocellular carcinoma. DNA Cell Biol 2020;39:2281-8.
206. Du J, Wan Z, Wang C, et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. Theranostics 2021;11:8185-96.
207. Liu J, Ye Z, Xiang M, et al. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. Biomaterials 2019;223:119475.
